Analysts Set Expectations for SCYNEXIS FY2029 Earnings

SCYNEXIS, Inc. (NASDAQ:SCYX) – Stock analysts at Brookline Capital Management issued their FY2029 earnings estimates for shares of SCYNEXIS in a report issued on Thursday, March 13th. Brookline Capital Management analyst K. Dolliver anticipates that the company will post earnings of $0.39 per share for the year.

SCYNEXIS (NASDAQ:SCYX) last released its quarterly earnings data on Wednesday, March 12th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.13. The company had revenue of $0.98 million during the quarter. SCYNEXIS had a negative net margin of 425.41% and a negative return on equity of 66.21%.

Separately, StockNews.com lowered shares of SCYNEXIS from a “hold” rating to a “sell” rating in a research note on Thursday, March 13th.

SCYNEXIS Stock Down 4.5 %

NASDAQ:SCYX opened at $1.05 on Monday. The company has a fifty day moving average of $1.07 and a 200-day moving average of $1.24. The firm has a market capitalization of $40.93 million, a P/E ratio of -1.42 and a beta of 1.67. SCYNEXIS has a twelve month low of $0.82 and a twelve month high of $3.07.

Institutional Trading of SCYNEXIS

Several hedge funds have recently modified their holdings of the stock. Squarepoint Ops LLC bought a new stake in SCYNEXIS during the 4th quarter valued at $53,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in SCYNEXIS by 22.0% during the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 195,393 shares of the company’s stock valued at $236,000 after purchasing an additional 35,233 shares in the last quarter. Millennium Management LLC bought a new stake in SCYNEXIS during the 4th quarter valued at $31,000. Jane Street Group LLC bought a new stake in SCYNEXIS during the 4th quarter valued at $32,000. Finally, Northern Trust Corp increased its stake in SCYNEXIS by 51.9% during the 4th quarter. Northern Trust Corp now owns 153,518 shares of the company’s stock valued at $186,000 after purchasing an additional 52,466 shares in the last quarter. Institutional investors own 54.37% of the company’s stock.

SCYNEXIS Company Profile

SCYNEXIS, Inc, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.